Streetbeat News

Stock Prices

MU

Morgan Stanley analyst Joseph Moore has maintained an Underweight rating on Micron Technology (NASDAQ:MU) but increased the price target from $58.5 to $71.5.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:58 pm

GSK

GSK plc announced positive Phase 3 trial results for belantamab mafodotin, showing significant improvement in progression-free survival for multiple myeloma compared to the standard of care. Despite previous setbacks with FDA and EMA regulatory issues, the encouraging data could signal a potential comeback for the drug, marketed as Blenrep. GSK shares saw minimal change in premarket trading.

Portfolio Pulse from Vandana Singh

November 27, 2023 | 12:57 pm

LUV

Raymond James analyst Savanthi Syth has maintained an Outperform rating on Southwest Airlines (NYSE:LUV) but lowered the price target from $36 to $34.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:54 pm

FSR

LCID

RIVN

TSLA

Needham analyst Chris Pierce reiterated a Buy rating and $25 price target for Rivian (RIVN), keeping it on the firm's 'Conviction List'. He downgraded Lucid (LCID) from Buy to Hold, citing uninspiring Q3 results and tempered expectations for technology licensing to Aston Martin. Pierce also holds Hold ratings on Tesla (TSLA) and Fisker (FSR), expressing concerns over Tesla's margin profile and skepticism about its growth levers. Rivian is seen as an 'underappreciated winner' in the EV transition, being supply-constrained with pricing power and potential for market expansion.

Portfolio Pulse from Shanthi Rexaline

November 27, 2023 | 12:51 pm

CSLR

Complete Solaria, presumably with the ticker CSLR, has announced that its founder, Will Anderson, will continue in his role as Interim CEO. No further details about the duration of his tenure or the reasons for the decision were provided in the article.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:32 pm

TRDA

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on Entrada Therapeutics (NASDAQ:TRDA) but has reduced the price target from $25 to $20.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:26 pm

ADI

CHUY

DY

NVDA

Analysts with high accuracy rates have made recent stock picks, with Aaron Rakers of Wells Fargo maintaining an Overweight rating on NVIDIA (NVDA) and raising the target to $675, implying a 41% upside. Matt Bryson of Wedbush reiterated an Outperform rating on NVDA with a $600 target. William Stein of Truist Securities maintained a Buy rating on Analog Devices (ADI) with a reduced target of $206. Brian Mullan of Piper Sandler kept a Neutral rating on Chuy's Holdings (CHUY) with a target of $39. Alex Rygiel of B. Riley Securities maintained a Neutral rating on Dycom Industries (DY) with a target of $101.

Portfolio Pulse from Lisa Levin

November 27, 2023 | 12:07 pm

CRNC

Cerence (NASDAQ:CRNC) reported Q4 earnings with an EPS of $0.09, missing the estimate of $0.15 by 40%. Despite the miss, revenue increased by $22.62 million compared to the same period last year. In the previous quarter, Cerence beat the EPS estimate but the share price fell by 1.87% the following day.

Portfolio Pulse from Benzinga Insights

November 27, 2023 | 12:05 pm

CCI

DIS

QQQ

SPY

ZS

U.S. stocks are expected to pause after recent gains, with a data-heavy week ahead potentially influencing market direction. Last week, major indices like the Nasdaq Composite, S&P 500, and Dow Industrials posted their fourth consecutive week of gains. Analysts anticipate a year-end rally based on historical patterns. Futures indicate a modestly lower opening, with SPY and QQQ slightly down in premarket trading. Walt Disney Co. (DIS) shares fell premarket after a weak box office performance, while Crown Castle Inc. (CCI) rose after Elliott Investment Management reportedly built a significant stake. Zscaler, Inc. (ZS) is set to release quarterly results. Crude oil prices dropped ahead of the OPEC+ meeting, and the 10-year Treasury note yield decreased slightly.

Portfolio Pulse from Shanthi Rexaline

November 27, 2023 | 12:04 pm

CRNC

Cerence Inc. (CRNC) reported a significant decline in its Q4 financial results, with adjusted earnings per share (EPS) dropping to $(0.14) from $0.09 year-over-year (YoY), and sales falling to $58.14 million from $80.76 million YoY, representing a 255.56% decrease in EPS and a 28.01% decrease in sales.

Portfolio Pulse from Benzinga Newsdesk

November 27, 2023 | 12:03 pm